| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/12/2011 | US20110110913 Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
| 05/12/2011 | US20110110904 Nutritional composition containing oligosaccharide mixture |
| 05/12/2011 | US20110110902 Means and methods for counteracting, delaying and/or preventing heart disease |
| 05/12/2011 | US20110110896 Modulating levels of RNA-binding proteins for the treatment of breast cancer |
| 05/12/2011 | US20110110891 Methods of Treating Hepatitis C Virus Infection |
| 05/12/2011 | US20110110890 Novel Inhibitors of Hepatitis C Virus Replication |
| 05/12/2011 | US20110110889 Raf inhibitor compounds and methods of use thereof |
| 05/12/2011 | US20110110886 Small molecule inhibitors of autotaxin and methods of use |
| 05/12/2011 | US20110110885 Bioactive Depside and Anthocyanin Compounds, Compositions, and Methods of Use |
| 05/12/2011 | US20110110884 Immunotherapy for immune suppressed patients |
| 05/12/2011 | US20110110883 Methods of altering an immune response induced by cpg oligodeoxynucleotides |
| 05/12/2011 | US20110110882 Cross-linked compositions |
| 05/12/2011 | US20110110880 Nicotine lozenge compositions |
| 05/12/2011 | US20110110874 Cosmetic Compositions |
| 05/12/2011 | US20110110870 Skin care compositions comprising phenoxyalkyl amines |
| 05/12/2011 | US20110110869 Stable hydroalcoholic compositions |
| 05/12/2011 | US20110110868 Functionalized Magnetic Nanoparticles and Methods of Use Thereof |
| 05/12/2011 | US20110110861 Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells |
| 05/12/2011 | US20110110860 Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter |
| 05/12/2011 | US20110110859 Protein |
| 05/12/2011 | US20110110850 Compounds for therapy and diagnosis |
| 05/12/2011 | DE102009053259A1 Use of hexosamine compounds and their analogs as pharmaceutical product, which inhibits the proliferation of trypanosomes, and thus for the treatment of trypanosome-induced disease |
| 05/12/2011 | DE102009053157A1 Arzneimittel enthaltend Cholin Medicines containing choline |
| 05/12/2011 | CA2789236A1 Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| 05/12/2011 | CA2781322A1 Use of danshensu, notoginsenoside r1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder |
| 05/12/2011 | CA2780925A1 Compositions for enhancing hair growth |
| 05/12/2011 | CA2780428A1 Tablet formulations of neratinib maleate |
| 05/12/2011 | CA2780332A1 Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| 05/12/2011 | CA2780274A1 Fragmented hydrogels |
| 05/12/2011 | CA2780268A1 Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
| 05/12/2011 | CA2780267A1 Compositions and methods for stimulating hair growth |
| 05/12/2011 | CA2780205A1 Methods of treating elevations in mtor signaling |
| 05/12/2011 | CA2780199A1 Pharmaceutical composition containing choline |
| 05/12/2011 | CA2780190A1 Compounds and methods for kinase modulation, and indications therefor |
| 05/12/2011 | CA2780149A1 Ire-1.alpha. inhibitors |
| 05/12/2011 | CA2780145A1 Therapeutic compounds |
| 05/12/2011 | CA2780136A1 Compounds inhibitors of enzyme lactate dehydrogenase (ldh) and pharmaceutical compositions containing these compounds |
| 05/12/2011 | CA2780128A1 Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| 05/12/2011 | CA2780111A1 Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors |
| 05/12/2011 | CA2780040A1 4r,5s-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity |
| 05/12/2011 | CA2780034A1 Benzimidazole-imidazole derivatives |
| 05/12/2011 | CA2779989A1 Quinazoline compounds |
| 05/12/2011 | CA2779951A1 Imidazopyridine derivatives |
| 05/12/2011 | CA2779948A1 Carboxy oxazole or thiazole compounds as dgat-1 inhibitors useful for the treatment of obesity |
| 05/12/2011 | CA2779935A1 Heterocyclic sulfonamide derivatives useful as mek inhibitors |
| 05/12/2011 | CA2779889A1 A method to enhance endurance |
| 05/12/2011 | CA2779797A1 Pharmaceutical solid dosage form |
| 05/12/2011 | CA2779736A1 Stable pharmaceutical formulations comprising lubiprostone |
| 05/12/2011 | CA2779720A1 Multilayer pharmaceutical composition that can be dispersed in water and which contains a combination of antimalarial agents |
| 05/12/2011 | CA2779711A1 Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
| 05/12/2011 | CA2779681A1 Tryptophan hydroxylase inhibitors for the treatment of cancer |
| 05/12/2011 | CA2779642A1 Enzyme inhibiting compounds |
| 05/12/2011 | CA2779574A1 Novel kinase modulators |
| 05/12/2011 | CA2779457A1 Methods for treating attention-deficit/hyperactivity disorder |
| 05/12/2011 | CA2779442A1 Methods for treating fibromyalgia syndrome |
| 05/12/2011 | CA2779424A1 Oral formulations of a hedgehog pathway inhibitor |
| 05/12/2011 | CA2779423A1 Benzodiazepine bromodomain inhibitor |
| 05/12/2011 | CA2779369A1 Composition, method, and kit for alpha-1 proteinase inhibitor |
| 05/12/2011 | CA2779355A1 Benzodiazepine bromodomain inhibitor |
| 05/12/2011 | CA2779147A1 Rosacea topical skin treatment method and formulation |
| 05/12/2011 | CA2779070A1 New therapeutic approaches for treating alzheimer disease |
| 05/12/2011 | CA2779005A1 Delivery carrier |
| 05/12/2011 | CA2778940A1 Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives |
| 05/12/2011 | CA2778907A1 Deuterated 5,6-dihydro-1h-pyridin-2-one compounds |
| 05/12/2011 | CA2778825A1 Treatment of sunburn using analgesics and antihistamines |
| 05/12/2011 | CA2778431A1 Use of synergistic combinations of an avermectin and an antineoplastic compounds for the treatment of hematological malignancies |
| 05/12/2011 | CA2778161A1 Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
| 05/12/2011 | CA2778115A1 Imidazole derivatives as ido inhibitors |
| 05/12/2011 | CA2778081A1 Devices, methods, and composition for controlling infections |
| 05/12/2011 | CA2778015A1 Bisphosphonate compounds for treating bone metabolism disorders |
| 05/12/2011 | CA2778003A1 Stable thickener formulations |
| 05/12/2011 | CA2777455A1 Novel 1,3-oxazolidine compounds and their use as renin inhibitors |
| 05/12/2011 | CA2777352A1 A novel process for the preparation of prostaglandins and intermediates thereof |
| 05/12/2011 | CA2776944A1 Combinations of a pi3k inhibitor and a mek inhibitor |
| 05/12/2011 | CA2775599A1 Bazedoxifene formulations with antioxidants |
| 05/12/2011 | CA2774054A1 Nutritional supplements for relief of dry eye |
| 05/12/2011 | CA2774046A1 Compositions comprising phenylsulfamic acids and their use for treating colitis |
| 05/12/2011 | CA2774043A1 Prolyl hydroxylase inhibitors |
| 05/12/2011 | CA2774039A1 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
| 05/11/2011 | EP2319926A1 DSRNA for treating viral infection |
| 05/11/2011 | EP2319925A2 Therapeutic uses of inhibitors of RTP801 |
| 05/11/2011 | EP2319917A2 Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
| 05/11/2011 | EP2319873A1 Dextran for treating lung cancer |
| 05/11/2011 | EP2319868A1 Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques |
| 05/11/2011 | EP2319856A1 Methods and compositions for treating hepatitis c virus |
| 05/11/2011 | EP2319853A1 Process for the production of 2'-branched nucleosides |
| 05/11/2011 | EP2319847A2 Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP |
| 05/11/2011 | EP2319846A1 Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone |
| 05/11/2011 | EP2319844A1 Tiotropium salts, method for creating same and medicinal formulations containing same |
| 05/11/2011 | EP2319843A1 Substituted pyrrole derivatives and their use as HMG-CO inhibitors |
| 05/11/2011 | EP2319841A1 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| 05/11/2011 | EP2319840A1 Aminopropylidene derivative |
| 05/11/2011 | EP2319839A1 Quinazolinone derivatives and their use as CB agonists |
| 05/11/2011 | EP2319838A1 Therapeutic Molecules and Methods-1 |
| 05/11/2011 | EP2319835A1 Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative having substituted oxy group |
| 05/11/2011 | EP2319831A1 Novel pyrrole derivative having, as substituents, ureide group, aminocarbonyl group and bicyclic group which may have substituent |
| 05/11/2011 | EP2319829A1 9-substituted tetracycline compounds |
| 05/11/2011 | EP2319828A2 Substituted tetracycline compounds |
| 05/11/2011 | EP2319826A1 Succinate salt of O-desmethyl-venlafaxin |
| 05/11/2011 | EP2319585A1 Pharmaceutical products and compositions comprising salmeterol, fluticasone and ipratropium or tiotropium |